Truist Downgrades GitLab Amid Rising Competitive and Execution Risks
Truist cuts GitLab rating to Hold and lowers its price target, citing low visibility, execution risks, and competitive pressure from GitHub’s lower-priced enterprise tier.
Truist cuts GitLab rating to Hold and lowers its price target, citing low visibility, execution risks, and competitive pressure from GitHub’s lower-priced enterprise tier.
Ross Stores surprises with strong fourth-quarter profits and sales growth, driven by rising same-store sales. The off-price retailer eyes continued momentum in 2026 amid economic challenges.
GitLab beats Q4 estimates with $260.4M in revenue (+23% YoY) and $0.30 non-GAAP EPS. The company also announced a $400M share repurchase program. FY2027 guidance calls for $1.10–$1.12B in revenue, coming in below consensus.
Moderna agrees to $2.25B settlement with Arbutus Biopharma and Genevant, paying $950M upfront + up to $1.3B contingent. Ends all COVID vaccine patent litigation worldwide.